HTA is shifting from one-time appraisal to lifecycle value assessment
Accelerated and conditional approvals now push much of a technology’s evidence into the post-launch setting. Decision-makers have to judge value as data matures, not just at market entry.
Traditional point-in-time HTA does not fit that reality. Lifecycle HTA connects early planning, initial appraisal, managed access, post-launch evidence, and reassessment into one prospectively designed sequence. Uncertainty at launch is managed, not assumed away.
Real-world evidence, patient-reported outcomes, and equity are what reduce that uncertainty and refine value over time. Their use in HTA, though, is still inconsistent and often fragmented.
Three evidence pillars
The inputs that refine value across the lifecycle
Each pillar answers a question that clinical trial data at launch cannot fully address on its own.
How the technology performs in practice
Registries, claims data, and electronic health records show effectiveness and use across broader populations over time.
- Effectiveness and safety in broader populations
- Long-term outcomes and durability
- Real-world utilization patterns
- Inputs for economic evaluation
The value clinical endpoints miss
Direct patient input on quality of life, symptom burden, and treatment impact, moved from supporting detail toward a formal decision input.
- Value judgments when clinical outcomes are uncertain
- Support for continuation or discontinuation
- Benefit beyond traditional endpoints
Whether value holds across populations
Access and outcomes measured across groups, not only on average, so disparities surface in the evidence rather than in hindsight.
- Patient and caregiver burden
- Real-world access and treatment complexity
- Population-level disparities in access and outcomes
From evidence to decisions
Turning post-launch data into decisions, not isolated analyses
A lifecycle approach only creates value when accumulating data changes a decision. Reassessment is triggered as key uncertainties resolve: maturing outcomes, evolving pathways, and new real-world and patient-reported evidence.
Stopping & continuation rules
Criteria that determine what happens as evidence matures- Align data with decisions. Evidence should be designed around defined decision points, not collected in isolation.
- Connect the evidence types. Clinical, economic, and patient-centered outcomes work as one system, not parallel inputs.
- Let value evolve. Reassessment updates cost-effectiveness through targeted parameter changes as outcomes mature and pathways shift.
Without integration, lifecycle HTA risks being structurally robust but analytically constrained.
Build value assessment that adapts as evidence matures
The full white paper covers early access and reassessment pathways across France and the UK, how evidence sources shift by therapeutic area, and recent NICE appraisals in lung cancer where updated survival and real-world data reshaped reimbursement.
Download the Full White PaperReferences
Full citation list is included in the downloadable white paper. Sources include lifecycle HTA frameworks (Trowman et al.; Pichler et al.; Kirwin et al.), NICE managed access and Early Value Assessment methods, HAS early access program data, and NICE technology appraisals TA770 and TA1071.
